

# Antje Neeb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5514065/publications.pdf>

Version: 2024-02-01

20  
papers

1,659  
citations

643344

15  
h-index

843174

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

3174  
citing authors

#	ARTICLE	IF	CITATIONS
1	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. <i>Cancer Research</i> , 2022, 81, 1087-1100.	0.4	23
2	Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. <i>European Urology Focus</i> , 2022, 8, 1157-1168.	1.6	26
3	Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3104-3115.	3.2	12
4	Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3509-3525.	3.2	11
5	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , 2021, 79, 200-211.	0.9	76
6	Targeting the p300/CBP Axis in Lethal Prostate Cancer. <i>Cancer Discovery</i> , 2021, 11, 1118-1137.	7.7	124
7	Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. <i>Clinical Cancer Research</i> , 2021, 27, 2340-2351.	3.2	10
8	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. <i>Science</i> , 2021, 374, 216-224.	6.0	135
9	HER3 Is an Actionable Target in Advanced Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 6207-6218.	0.4	25
10	Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. <i>European Urology</i> , 2019, 76, 469-478.	0.9	269
11	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 676-685.	0.9	62
12	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). <i>Clinical Cancer Research</i> , 2018, 24, 3149-3162.	3.2	111
13	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 192-208.	3.9	266
14	IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. <i>Nature</i> , 2018, 559, 363-369.	13.7	258
15	Alternative splicing in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 663-675.	12.5	142
16	Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. <i>ELife</i> , 2017, 6, .	2.8	32
17	Superporous Poly(ethylene glycol) Diacrylate Cryogel with a Defined Elastic Modulus for Prostate Cancer Cell Research. <i>Small</i> , 2016, 12, 3985-3994.	5.2	20
18	Cancer Treatment: Superporous Poly(ethylene glycol) Diacrylate Cryogel with a Defined Elastic Modulus for Prostate Cancer Cell Research (Small 29/2016). <i>Small</i> , 2016, 12, 4020-4020.	5.2	1

#	ARTICLE	IF	CITATIONS
19	Control of Steroid Receptor Dynamics and Function by Genomic Actions of the Cochaperones p23 and Bag-1L. Nuclear Receptor Signaling, 2014, 12, nrs.12005.	1.0	16
20	Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer. Oncotarget, 2014, 5, 8681-8689.	0.8	39